Last reviewed · How we verify
Asthma management
Approved treatments
- Cutivate · Teva Pharm
- Omnaris · Takeda Gmbh
Omnaris works by activating the glucocorticoid receptor to reduce inflammation in the airways. - Alocril · AbbVie
- Omnaris · Covis
Omnaris works by binding to the glucocorticoid receptor, which then reduces inflammation in the airways. - Verdeso · Padagis Us
- Intal · Pfizer
- Flonase · GSK (GlaxoSmithKline)
- Cromoglicate · LEO Pharma
- Beconase Aq
- Flixotide · Mundipharma Research Limited
- Pulmicort Respules · AstraZeneca K.K.
- Rhinocort · Marinomed Biotech AG
- Singulair · Genuine Research Center, Egypt
- Nasonex · University of Alberta
- Butanefrine
Butanefrine works by stimulating the body's natural responses to constrict blood vessels and increase airway resistance. - Rodinolone
- Fluticason · Creighton University
- Theophyllin · University of Bergen
- Epipen · Pfizer Inc.
Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation. - Norepinephrine Bitartrate In 5% Dextrose · Pfizer
Norepinephrine constricts blood vessels and stimulates the heart. - Aerospan Hfa
- Bupivacaine Hydrochloride And Epinephrine · Pfizer Inc.
Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels. - Diphyllin
- Metaproterenol
- Elocon · Merck & Co.
Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body. - Brethine
- Accolate · Strides Pharma Intl
- Tornalate · Sanofi
- Beclometasone · Imperial College London
- Epinephrin · United States Naval Medical Center, San Diego
- Aminophyllin · University of Padova
- Noradrenaline · Tanta University
- Cromoglycate · Vishwajit Nimgaonkar, MD PhD
- Singulair · Merck & Co.
Leukotriene receptor antagonist (LTRA) that blocks CysLT1 receptors, reducing bronchoconstriction, mucus production, and airway inflammation. - MOMETASONE
12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Asthma management patent landscape — cliff calendar, originator estates, attackable patents
- Asthma management treatment landscape brief
- Asthma management treatment updates RSS
Frequently asked questions about Asthma management
What drugs treat Asthma management?
Tracked treatments include Cutivate, Omnaris, Alocril, Verdeso, Intal, Flonase, Cromoglicate, Beconase Aq.
What is the treatment for Asthma management?
Standard treatment for Asthma management includes Cutivate, Omnaris, Alocril, Verdeso, Intal. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Asthma management patent cliff · Asthma management CI report
- Treatment: Cutivate · Teva Pharm
- Treatment: Omnaris · Takeda Gmbh
- Treatment: Alocril · AbbVie
- Treatment: Omnaris · Covis
- Treatment: Verdeso · Padagis Us
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing